Patent ID: 6531485
Filing Date: 2003-03-11
Classification: A61P,C07C,C07D

Abstract:
A method for treating a mammal having a condition which presents with low bone mass comprising administering to said mammal a therapeutically effective amount of a compound of the formula IA a prodrug thereof or a pharmaceutically acceptable salt of said compound or said prodrug whereinA is hydrogen or hydroxy; B is propylene, propenylene or propynylene; Q is propylene, â€”CH2OCH2â€”, thiazolyl, pyridyl, phenyl or thienyl; Z is carboxyl, (C1-C6)alkoxycarbonyl, tetrazolyl, 1,2,4-oxadiazolyl or 5-oxo-1,2,4-oxadiazolyl; K is ethylene or ethynylene; L is a bond or â€”COâ€”; M is â€”Ar, â€”Ar1â€”Vâ€”Ar2, â€”Ar1â€”Sâ€”Ar2 or â€”Ar1â€”Oâ€”Ar2 wherein Ar, Ar1 and Ar2 are each independently a fully saturated, partially unsaturated or fully unsaturated five to eight membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or, a bicyclic ring consisting of two fused partially saturated, fully saturated or fully unsaturated five and/or six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen, or, a tricyclic ring consisting of three fused partially saturated, fully saturated or fully unsaturated five and/or six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen, any of said partially saturated or fully saturated rings optionally having one or more oxo groups substituted on carbon, said Ar, Ar1 and Ar2 moieties are each independently optionally substituted, on one ring if the moiety is monocyclic, on one or both rings if the moiety is bicyclic, or on one, two or three rings is the moiety is tricyclic, on carbon with up to three substituents independently selected from R1, R2 and R3 wherein R1, R2 and R3 are hydroxy, nitro, halo, (C1-C7)alkoxy, (C1-C4)alkoxy(C1-C4)alkyl, (C1-C4)alkoxycarbonyl, (C1-C7)alkyl, (C2-C7)alkenyl, (C2-C7)alkynyl, (C3-C7)cycloalkyl, (C3-C7),cycloalkyl(C1-C4)alkyl, (C3-C7)cycloalkyl(C1-C4)alkanoyl, formyl, (C1-C8)alkanoyl, (C1-C6)alkanoyl(C1-C6)alkyl, aminocarbonylamino or mono-N-, di-N,N-, di-N,Nâ€²- or tri-N,N,Nâ€²â€”(C1-C4)alkyl substituted aminocarbonylamino, (C1-C4)alkanoylamino, (C1-C4)alkoxycarbonylamino, sulfonamido, hydroxysulfonyl, (C1-C4)alkylsulfonamido, amino, mono-N- or di-N,Nâ€”(C1-C4)alkylamino, carbamoyl, mono-N- or di-N,Nâ€”(C1-C4)alkylcarbamoyl, cyano, thiol, (C1-C6)alkylthio, (C1-C6)alkylsulfinyl, (C1-C4)alkylsulfonyl or mono-N- or di-N,Nâ€”(C1-C4)alkylaminosulfinyl; R1, R2 and R3, when containing an alkyl, alkenyl, alkylene or alkenylene moiety, are optionally straight or branched and are optionally mono-, di- or tri-substituted on carbon independently with halo or hydroxy; and V is a bond, â€”COâ€” or (C1-C3)alkylene optionally mono- or di-substituted independently with hydroxy or fluoro, provided that (1) when L is â€”COâ€”, A is hydroxy; and (2) when L is a bond and M is phenyl, said phenyl is substituted with one to three substituents selected from R1, R2 and R3.